To think differently, if specific agonists or small‐molecule inhibitors targeting specific ZNFs are investigated and developed, is it possible to reverse the state of the WNT and JAK‐STAT pathways in CRC and thus influence the course of CRC development? Here, SOAT1 is linked to colorectal carcinoma.